Factor VII Deficient Plasma

FOR RESEARCH USE ONLY.

NOT FOR USE IN DIAGNOSTIC PROCEDURES.

INTENDED USE:
The kit is proposed for the measurement of Factor VII (FVII or Preconvertin) activity in human citrated plasma using a clotting method, triggered with calcium thromboplastin. This kit is for research use only and should not be used for patient diagnosis or treatment.

ASSAY PRINCIPLE:
The method is a clotting assay where all the clotting factors are present (constant and in excess, brought by the deficient plasma), excepted for FVII, which is brought by the diluted tested plasma, and clotting is triggered with calcium thromboplastin. FVII is the limiting factor and clotting time is inversely proportional to the concentration of FVII. There is an inverse linear relationship, on a bilogarithmic graph paper, between the FVII concentration and the corresponding clotting time.

ASSAY SPECIMEN:
Human plasma obtained from Trisodium Citrate anticoagulated blood.

REAGENTS:
- Pipettes with dispensing volumes of 20 µL, 50 µL and 100 µL; or with a variable dispensing volume from 50 µL to 1,000 µL.
- Semi-automatic or automatic coagulation instrument, or fibrrometer or electromagnetic water bath; stop watch.
- Distilled water.
- Imidazole buffer (ex AR021A/AR021K/AR021L).
- Normal human citrated plasma pool or Factor VII calibrator (BIOPHEN Plasma Calibrator - #222101).
- Normal and Abnormal quality control plasmas, titrated for Factor VII (BIOPHEN Normal Control Plasma - #223201 and BIOPHEN Abnormal Control Plasma - #223301).
- Calcium Thromboplastin (such as rabbit brain thromboplastin).

REAGENT PREPARATION AND STABILITY:
In the original package, and before any use, when stored at 2-8°C, the reagent is stable until the expiration date printed on the kit.
- Reagent Preparation:
  - Restore the vial with 1 ml of distilled water; mix gently until complete dissolution of the content; homogenize before use.
  - Reagent stability following reconstitution:
    - When opened and protected from any contamination, the reconstituted plasma is stable for:
      - 8 hours at room temperature (18-25°C)
      - 24 hours at 2-8°C
    - 2 months, frozen at 20°C or below, in its original vial, or in a plastic tube (before use, thaw in a water bath at 37°C, for at least 15 min).

Note: Plasmas used for the Deficient Plasma preparation were tested with registered methods and found negative for HIV antibodies, HBs Ag and HCV antibodies. However, no assay may warrant the total absence of infectious agents. Any product of human origin must then be handled with all the required caution, as being potentially infectious.

Note: The stability studies at 30°C show that the reagent can be stored at room temperature without damage.

SAMPLE COLLECTION AND PREPARATION:
Blood (9 vol.) must be collected on 0.109M trisodium citrate anticoagulant (1 vol.); plasma supernatant is decanted following a 20 min. centrifugation at 2,500 g; citrated plasma must be tested within 4 hours when stored at room temperature (20-25°C). Do not store the plasma at 2-8°C.

Refer to GC/NT or NQCLS guidelines for further instructions on specimen collection, handling and storage. Discard any sample with an unusual aspect.

PROTOCOL:
Calibration:
Preparation of normal citrated human pooled plasma diluted 1:10 in imidazole buffer. By definition, this ten fold dilution of the normal citrated human plasma pool corresponds to a concentration of 100% of FVII. Using this preparation, the calibration curve is obtained as follows:

<table>
<thead>
<tr>
<th>Dilution</th>
<th>Plasma pool 1:10</th>
<th>Imidazole Buffer</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:100</td>
<td>0.060 mL</td>
<td>0.940 mL</td>
</tr>
<tr>
<td>1:10</td>
<td>0.125 mL</td>
<td>0.875 mL</td>
</tr>
<tr>
<td>1:4</td>
<td>0.250 mL</td>
<td>0.750 mL</td>
</tr>
<tr>
<td>1:2</td>
<td>0.500 mL</td>
<td>0.500 mL</td>
</tr>
<tr>
<td>1:1</td>
<td>1.000 mL</td>
<td>0.000 mL</td>
</tr>
</tbody>
</table>

*These complementary dilutions can be used when high accuracy is required for the low range (0-10%). The calibration curve can also be established with the BIOPHEN Plasma Calibrator (#222101), using the factor VII activity (C) indicated on the flyer for the lot used.

Preparation of tested plasma:
Tested plasma must be diluted 1:10 with imidazole type buffer. The diluted plasma must be tested within 2 hours.

Assay:
Manual Method:

Preincubate Calcium Thromboplastin at 37°C.
In a test tube, or a cuvette, introduce:
- 100 µL of FVII deficient Plasma.
- 100 µL of calcium solution or of tested plasma diluted 1:10.
Incubate for 1 min. at 37°C, and then introduce (starting the stop watch):
- 200 µL of Calcium Thromboplastin preincubated at 37°C.
Record the clotting time.

Automatic Method:
The assay can be used with the semi-automatic or automatic instruments, such as STA-R, KC-4, KC-10, BCT, BCS, etc...
The usual program used for testing the factors involved in the extrinsic pathway with a clotting based calcium thromboplastin method, and a specific deficient plasma, can be applied. The respective specimen and reagent volume ratios indicated for the manual method must be strictly respected. Usually, with automatic methods the volumes used for reagents and tested plasma (diluted 1:10) are half those recommended for the normal method.

With semi automatic or automatic instruments, especially those with a photometric detection of clot formation, clotting times to use to be slightly shorter than with the manual method.

EXPRESSION OF RESULTS:
On a bilogarithmic graph paper, plot on abscissae the FVII concentrations and on ordinates the corresponding clotting times. On the calibration curve obtained, interpolate directly the corresponding FVII concentration for the tested plasma.

Example of Calibration curve: This calibration curve is indicated as an example only. It was obtained with Neoplatin US from Diagnostica Stago, using a manual method.

QUALITY CONTROL:
The control is performed using commercially available control plasmas, titrated for FVII activity. Various control plasmas are available: BIOPHEN Normal Control Plasma (ref 223301); BIOPHEN Abnormal Control Plasma (ref 223301). Use of quality control plasmas allows validating the calibration curve, as well as the homogeneous reactivity of the assay from run to run, and from series to series, when using a same lot of reagents.

CAUTIONS AND LIMITATIONS:
- Sampling must be performed with great care, avoiding any blood activation. Discard any plasma presenting an unusual aspect, or any sign of activation or clotting.
- It is recommended to perform all assays of fresh calibration points, specimen and controls successively without interruption, to obtain optimal performances of the assay.
- For a better accuracy, samples measured ≤10% can be tested at the 1:5 dilution, and obtained results divided by 2; for samples measured >100% (or ≥C%), the 1:20 dilution can be used and obtained results multiplied by 2.
- For a deficient sample: check the result by testing if necessary the 1:5 dilution (the obtained concentration must then be divided by 2); and, if another sample and/or method for the test plasma; check potential associated factor(s) deficiency.
- Thrombin inhibitors present in the tested sample may lead to an underestimation of the FVII concentration.
- Do not store the plasma at 2-8°C.
- The results obtained should only be used for research purposes only and not used for patient diagnosis or treatment.

NORMAL VALUES:
Normal values for Factor VII activity are usually > 60%.

APPLICATIONS:
The reagent is proposed for measuring Factor VII activity, by clotting assay.
- Lyophilized, human citrated plasma, deficient for FVII, for any in vitro protocol or research study where a source of human FVII deficient plasma is required.

ASSAY VARIATIONS:
The clotting times observed for this assay are obtained with Calcium Thromboplastin from Biomérieux (Calcium Thromboplastin) or from Diagnostica Stago (Neoplatin). They are expected ±20 seconds for the 100% FVII concentration. The obtained clotting times and assay performances can slightly vary according to the thromboplastin reagent type and lot, and the instrument used in the laboratory. Performances, as well as target values and acceptance ranges for each new lot of quality controls used, and the normal range, must then be confirmed (and adjusted if necessary) in the laboratory working conditions.

D750-02/DP/030-RUO